Amundi Has $42.97 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Amundi raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 79.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 117,205 shares of the biotechnology company's stock after purchasing an additional 51,885 shares during the quarter. Amundi owned 0.26% of United Therapeutics worth $42,969,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Newbridge Financial Services Group Inc. purchased a new stake in United Therapeutics in the 4th quarter worth about $25,000. Brooklyn Investment Group acquired a new position in shares of United Therapeutics in the 3rd quarter valued at about $33,000. MassMutual Private Wealth & Trust FSB increased its holdings in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 58 shares during the period. Jones Financial Companies Lllp increased its holdings in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after purchasing an additional 258 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $131,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Insiders Place Their Bets

In other news, Director Nilda Mesa sold 255 shares of the business's stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares in the company, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Louis W. Sullivan sold 26,209 shares of the business's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the transaction, the director now owns 5,051 shares in the company, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 116,464 shares of company stock valued at $42,396,244 in the last quarter. Insiders own 11.90% of the company's stock.

United Therapeutics Trading Up 0.9 %

UTHR stock opened at $307.09 on Thursday. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The company has a fifty day simple moving average of $351.85 and a 200 day simple moving average of $359.12. The firm has a market cap of $13.79 billion, a PE ratio of 13.49, a PEG ratio of 0.97 and a beta of 0.64.

Remove Ads

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the previous year, the business earned $4.36 EPS. As a group, analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on UTHR. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.